Biopsy Practices in DLBCL

Opinion
Video

Carla Casulo, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to provide clinical insights on biopsy practices and discuss the importance of cell of origin in treating diffuse large B-cell lymphoma (DLBCL).

Recent Videos
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Investigators are currently evaluating mosunetuzumab in relapsed disease or comparing it with rituximab in treatment-naïve follicular lymphoma.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Establishment of an AYA Lymphoma Consortium has facilitated a process to better understand and address gaps in knowledge for this patient group.
Adult and pediatric oncology collaboration in assessing nivolumab in advanced Hodgkin lymphoma facilitated the phase 3 SWOG S1826 findings.
Related Content
3 Things You Should Know About Immunotherapy in DLBCL

3 Things You Should Know About Immunotherapy in DLBCL

Matthew A. Lunning, MD;Grzegorz S. Nowakowski, MD
December 19th 2024
Article

Here are 3 things you should know about immunotherapy in diffuse large B-cell lymphoma.

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Collaboration Fosters Treatment Advancements for Young Lymphoma Populations

Andrew M. Evens, DO, MBA, MSc
November 18th 2024
Podcast

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Phase 3 data support tafasitamab plus lenalidomide/rituximab as a potential new standard of care in patients with relapsed/refractory follicular lymphoma.

PFS Boost Occurs With Tafasitamab Combo in R/R Follicular Lymphoma

Caroline Seymour
December 11th 2024
Article

Phase 3 data support tafasitamab plus lenalidomide/rituximab as a potential new standard of care in patients with relapsed/refractory follicular lymphoma.

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

Overcoming Physical and Social Barriers in the Lymphoma Field

Julie M. Vose, MD, MBA;Avyakta Kallam, MD
July 15th 2024
Podcast

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

Positive PFS and EFS Outcomes Were Elicited by Pirobrutinib in CLL and SLL

Positive PFS and EFS Outcomes Were Elicited by Pirobrutinib in CLL and SLL

Tony Berberabe, MPH
December 10th 2024
Article

Pirobrutinib sustained BTK inhibition and improved progression-free survival in patients with CLL and SLL, data from the phase 3 BRUIN CLL-321 trial showed.

Positive ORRs Yielded by Glofitamab Regimen in R/R Large B-Cell Lymphoma

Positive ORRs Yielded by Glofitamab Regimen in R/R Large B-Cell Lymphoma

Darlene Dobkowski, MA
December 10th 2024
Article

Glofitamab with polatuzumab vedotin benefited patients with high-grade B-cell lymphomas and who failed prior CAR T-cell therapy.